Health Care & Life Sciences » Pharmaceuticals | Cellectar Biosciences Inc.

Cellectar Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
424.80
367.20
362.50
356.70
1,546.00
82.30
Gross Income
424.80
367.20
362.50
356.70
1,546.00
82.30
SG&A Expense
10,880.20
9,301.90
8,191.70
9,093.10
12,054.90
11,573
EBIT
11,304.90
9,669.10
8,554.20
-
13,601.00
11,655.30
Unusual Expense
1,277.10
2,009.00
3,060.00
3,261.50
22.10
1,613.40
Non Operating Income/Expense
745.00
-
-
-
-
-
Interest Expense
9.30
446.30
0.80
1.50
1.00
-
Pretax Income
10,782.20
8,106.40
5,495.00
6,180.30
13,562.30
13,239
Consolidated Net Income
10,782.20
8,106.40
5,495.00
6,180.30
13,562.30
13,239
Net Income
10,782.20
8,106.40
5,495.00
6,180.30
13,562.30
13,239
Net Income After Extraordinaries
10,782.20
8,106.40
5,495.00
6,180.30
13,562.30
13,239
Net Income Available to Common
10,782.20
8,106.40
5,495.00
9,360.30
15,011.20
15,480.80
EPS (Basic)
380.00
177.00
70.30
21.40
10.70
5.23
Basic Shares Outstanding
27.90
45.90
78.20
436.70
1,403.10
2,962
EPS (Diluted)
385.83
176.51
70.27
21.44
10.70
5.23
Diluted Shares Outstanding
27.90
45.90
78.20
436.70
1,403.10
2,962
EBITDA
10,880.20
9,301.90
8,191.70
9,093.10
12,054.90
11,573
Non-Operating Interest Income
-
-
-
9.40
17.60
29.70
Preferred Dividends
-
-
-
3,180.00
1,448.90
2,241.80

About Cellectar Biosciences

View Profile
Address
100 Campus Drive
Florham Park New Jersey 07932
United States
Employees -
Website http://www.cellectar.com
Updated 07/08/2019
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.